Intellia Therapeutics, Inc. (NTLA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 42.44 |
| Open | 43.71 |
| Bid | 43.04 x 1000 |
| Ask | 43.57 x 800 |
| Day's Range | 40.90 - 43.72 |
| 52 Week Range | 32.44 - 104.87 |
| Volume | |
| Avg. Volume | 1,207,456 |
| Market Cap | 3.72B |
| Beta (5Y Monthly) | 1.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.06 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 101.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NTLA
Related Research
- Intellia Therapeutics, Inc.Analyst Report: Intellia Therapeutics, Inc.Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.RatingFair ValueEconomic Moat2 months agoMorningstar
- TheStreet.com
Does Intellia Therapeutics Stock Have Good Genes?
CRISPR editing firm Intellia Therapeutics was rated a new fundamental "overweight" (buy) by a sell-side firm Wednesday with a $67 price target. The On-Balance-Volume (OBV) line has been weak with a low just made in January. The weekly OBV line has struggled the past 18 months or so but may have made a low in January.
- InvestorPlace
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr
- InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,
